Related Experiment Video
Updated: Jun 24, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Update on targeted agents for adjuvant treatment of colon cancer in 2006
Aimery de Gramont1, Annette K Larsen, Christophe Tournigand
1Hôpital Saint-Antoine.
Abstract:
Due to its frequency and still too high mortality rate, colorectal cancer represents a major public health problem. The use of adjuvant chemotherapy has improved the prognosis for patients with this disease. Adjuvant chemotherapy regimens derive from the most active regimens in advanced colorectal cancer therapy. Recently, two monoclonal antibodies have shown activity in patients with advanced colorectal cancer: bevacizumab, which targets vascular endothelial growth factor (VEGF), has shown activity as first- and second-line therapy; and cetuximab, which targets the epidermal growth factor receptor (EGFR), has demonstrated activity as third-line therapy. The objective of this paper is to present the ongoing trials evaluating targeted therapies in adjuvant treatment for colon cancer. Duration of therapy, new agents, and combinations of targeted therapies are other critical issues for the future.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drugs for Treatment of Ulcerative Colitis in IBD
Treatment Resistent Cancers
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Treatment Resistant Cancers
